MHIET’s 500kW-Class Hydrogen Engine Generator Set Achieves Technology Readiness Level for Commercialization

TOKYO, June 24, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Engine & Turbocharger, Ltd. (MHIET), a part of Mitsubishi Heavy Industries (MHI) Group, previously achieved rated operation (435kW/1,500min-1) of a 500kW-class hydrogen engine generator set(1) at its demonstration facility using 100% hydrogen fuel. Recently, the company has…

DOCOMO Becomes First in Japan to Deploy Nokia’s AI-powered MantaRay AutoPilot for Automated Network Optimization

TOKYO, Japan, June 24, 2026 - (JCN Newswire via SeaPRwire.com) - NTT DOCOMO, INC. announced today that it has become the first company in Japan to deploy Nokia's MantaRay AutoPilot system, an AI-driven system that automatically optimizes mobile network quality, effective June 19.*1 To accelerate deployment, DOCOMO implemented MantaRay AutoPilot on…

Mitsubishi Power and LNGPH Sign Long-Term Deal for Gas Turbine Parts and Services to Advance Energy Resilience in the Philippines

Manila, Philippines, June 24, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Power, a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI), announced the signing of a Long-Term Parts and Services Agreement (LTPSA) between its Philippine after-sales arm MHI Power (Philippines) Plant Services Corporation (MHI-PSC) and LNGPH, through its…

Datavault AI Inc. (NASDAQ: DVLT) and WiSA Technologies Announce the Goho LS7 2.0 and 5.1 Home Theater Systems with WiSA E Wireless Connectivity

PHILADELPHIA, PA, June 23, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. (NASDAQ:DVLT), through its Acoustic Sciences division's WiSA Technologies, today announced integration of the WiSA E Enterprise module in the new LS7 2.0 and 5.1 wireless home audio and karaoke systems from Goho, a brand of Goldhorn. These…

Jacobson Pharma Announces FY2026 Annual Results

KEY HIGHLIGHTS- Revenue held steady at HK$1,569.5 million- Profit attributable to equity shareholders increased to HK$301.6 million- Recommended final dividend of HK4.75 cents per share- Strong demand for chronic disease medicines underpinned core performance amid normalised seasonal respiratory demand.- Expanded specialty medicines portfolio through 46 in-licensing agreements; secured 23 new…